Kornimate/medical-research-clean huggingface dataset:
cognitive motor therapy applications using videogame platform

Conditions: Stroke

Summary: this study designs and develops an evidence-based game approach that will enhance the investigators understanding and usability of electronic tools to measure cognitive and sensorimotor abilities in an inpatient rehabilitation stroke population.

the rehabilitation industry is the incipient stages of developing and using electronic based assessment and intervention tools. with the growing understanding of cognitive recovery following stroke, rehabilitation specialists are optimistic that appropriate rehabilitation interventions may optimize and enhance functional outcomes. the use of technology based assessments via video games may assist in a patient's cognitive recovery. design and development of an evidence-based game approach will enhance the investigators understanding and usability of electronic tools to measure cognitive and sensorimotor abilities. there is no intervention only an assessment for usability.

Eligibility criteria:
inclusion criteria: * new onset stroke * ability to follow one-step commands * all participants must be admitted to the inpatient rehabilitation unit at cedars-sinai medical center * scores needed for participation in study on the complex ideational material-short form from the boston diagnostic aphasia examination and the montreal cognitive assessment: * complex ideational material-short form from the boston diagnostic aphasia examination-participants must obtain a total score of at least 5/6 item pairs to participate * montreal cognitive assessment-participants must obtain a total score of 16 or greater and obtain a score of 6/6 on the orientation subtest * in order to participate, participants must meet both of the above criteria exclusion criteria: * patients who do not meet inclusion criteria as noted above.

Keywords: videogames; stroke
isoflavones for promoting calcium absorption and preventing bone loss in post menopausal women

Conditions: Osteoporosis; Osteopenia

Summary: estrogen is a hormone that helps prevent calcium loss and bone breakdown. during menopause, estrogen levels decrease. insufficient amounts of estrogen may lead to bone loss and possibly osteoporosis. isoflavones are natural compounds found in soy plants that may help provide protection against bone loss. this study will evaluate the effect of soy isoflavones on calcium absorption and bone loss in post menopausal women.

estrogen is a hormone that activates bone-forming cells and prevents calcium loss and bone breakdown. during menopause, estrogen levels decrease. insufficient amounts of estrogen may accelerate bone breakdown and inhibit the body's ability to create new bone, thereby leading to bone loss and possibly osteoporosis. various treatments have been developed to decrease bone loss in post-menopausal women. actonel, for example, is an fda-approved drug used to help prevent bone loss. phytoestrogens are plant compounds with a structure similar to estrogen. they have also been shown to help reduce the negative effects of menopause. isoflavones are a particular type of phytoestrogens that are found in soy plants and may act like estrogen in providing possible protection against bone loss. this study will compare the effects of isoflavones (including genistein, a type of isoflavone) versus actonel on calcium absorption and bone loss in post-menopausal women. participants in this double-blind cross-over study will first complete a screening process, which will include answering questions about their health habits, medical history, physical activity, and food patterns. they will then eat one soy bar daily for 3 days. on day 4, a urine sample will be taken to assess their ability to metabolize phytoestrogen from soybeans. participants will be randomly assigned to a specific treatment order. participants will receive 1-4 unique soy isoflavones, followed by actonel. treatment phases will be separated by a 50-day washout period. all participants will also take calcium and vitamin d supplements throughout the study. assessments will include bone density measurements, calcium absorption tests, and blood and urine tests. the study will last approximately 2.5 years.

Eligibility criteria:
inclusion criteria: * at least 4 years post-menopausal exclusion criteria: * not currently taking estrogen replacement therapy or undergoing any treatment for osteoporosis * diagnosis of breast cancer * results of mammogram suggesting breast cancer

Keywords: bone resorption phytoestrogens calcium genistein equol
specialized treatment, rehabilitation and outcome in patients with prolonged critical illness

Conditions: Critical Illness

Summary: this prospective observational study aims to describe the outcome for patients with persistent or chronic critical illness treated at remeo, a clinic specialized for patients in need of prolonged intensive care and intensive care rehabilitation in sweden. patients' disease characteristics and the treatment in multidisciplinary patient centered teams for intensive care, weaning from mechanical ventilation and simultaneous rehabilitation will be described. patients will be followed one year after discharge to document health related quality of life, physical function, frailty, mental illness and used health care resources.


Eligibility criteria:
inclusion criteria: admission to unit (remeo, stockholm, sweden) treated for prolonged critical illness exclusion criteria: treated less than 48 hours at unit (remeo, stockholm, sweden)

Keywords: persistent critical illness chronic critical illness prolonged intensive care weaning from mechanical ventilation decannulation multidisciplinary team intensive care rehabilitation
effects of an external oral irrigation device on patients with dry mouth

Conditions: Xerostomia

Summary: the purpose of this research study is to test the effectiveness of treating dry mouth through water rehydration using this extra oral water pump/irrigation device.

dry mouth causes difficulty with chewing, swallowing, speech, and increases the risk dental cavities. it also can cause discomfort in the mouth, and a loss of general quality of life. the oral irrigation device supplies a small amount of water to participant's mouth through a small tube that is placed in the corner of the mouth throughout the time participants wear it. in this study, participants will be asked to: 1. visit the dental school clinic two (2) times for study visits. 2. wear the oral irrigation device as directed by the investigator. 3. keep notes at home. 4. answer survey questions during both dental visits about dry mouth symptoms. 5. give permission for the researchers to collect information about medications or health conditions that contribute to dry mouth from participant's medical records.

Eligibility criteria:
inclusion criteria: * patients who report xerostomia (dry mouth) and are diagnosed after testing with hypofunctioning salivary glands exclusion criteria: * patient who after testing do not exhibit salivary hypofunction * children * patient with limited english proficiency
the effect of acupuncture in chemotherapy-induced nausea and vomiting

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: nausea and vomiting are the most common symptoms experienced by cancer patients after chemotherapy. some patients have to endure such unpleasant symptoms even after using of antiemetic or anti-vomiting medications.the purpose of this study is to assess the therapeutic effects and safety of acupuncture for chemotherapy-induced nausea and vomiting on patients with malignancy


Eligibility criteria:
inclusion criteria: 1. patients with definite pathological diagnosis of lung cancer, breast cancer, and gynecological cancer.they haven't receive any chemotherapy or radiotherapy treatment for three months prior to join this study. 2. aged 18-75. 3. patients will receive chemotherapy treatment which included cisplatin, anthracycline or taxane during the study period. 4. ecog score is between 0 and 2. 5. the patients are diagnosed with insufficiency of spleen-qi and stomach-qi,reverse ascending of stomach-qi in traditional chinese medicine theory. 6. the expected lifetime of the patient is longer than 6 months. 7. patients willing to participate in the study and sign the consent form. exclusion criteria: 1. patients have serious disease in cardiovascular system ,liver system,kidney system, immune systems and hemopoietic system. 2. pregnant and lactating women. 3. patients have intractable vomiting caused by malignant brain metastases, intracranial hypertention, digestive tract obstruction, severe liver or renal dysfunction, brain tumors, cerebrovascular disease, or other reasons. 4. patients with coagulopathy, thrombocytopenia, or suffering from bleeding disorders. 5. patients have been definitely diagnosed with depression, anxiety disorders and psychosis 6. patients with sepsis or bacteremia. 7. patients have lymphedema in acupuncture stimulation area. 8. patients who are afraid of acupuncture stimulation or allergic to stainless steel needles can't participate in this study.

Keywords: acupuncture chemotherapy-induced nausea and vomiting
double blind, randomized trial of bosentan for sarcoidosis associated pulmonary hypertension

Conditions: Sarcoidosis; Pulmonary Arterial Hypertension

Summary: patients with advanced sarcoidosis often develop pulmonary hypertension. pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal. since this pressure is higher, it is harder for the heart to pump the blood through the lungs to the left side of the body. if the blood can not get through the lungs, it can not get pumped through the rest of the body. this leads to weakness and shortness of breath. this type of hypertension does not usually respond to regular blood pressure medicines. the purpose of this study is to determine if bosentan (tracleer) will help sarcoidosis associated pulmonary hypertension.

patients will be randomized in 2:1 manner to receive either bosentan or placebo for 16 weeks. after 16 weeks, there will be an additional 32 weeks of an open label extension.

Eligibility criteria:
inclusion criteria: * patients with known sarcoidosis 21. * age 18 or greater * patients with documented pulmonary hypertension with a pa mean \> 25 mm hg as measured by cardiac catheterization within six months of entry into the study. pulmonary artery occluding pressure and or left ventricular end diastolic pressure must be less than 15 mm hg. * patients with who class ii or iii * six minute walk distance of between 100 to 500 meters * patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab * patients able to provide written consent exclusion criteria: * patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n the prior 28 days. patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker. * patients with severe airway obstruction as defined by fev1/fvc of less than 35% * patients with world health organization (who) class iv status. * patients who are pregnant or breast feeding * patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35% * cardiac index \ 15 mm hg * significant liver dysfunction not due to sarcoidosis. * patients with severe other organ disease felt by investigators to impact on survival during the course of the study. * patients unable to perform the 6 minute walk study

Keywords: sarcoidosis
comparison of two spinal needles regarding postdural puncture headache

Conditions: Anesthesia; Adverse Effect, Spinal and Epidural, Headache; Complications; Anesthesia, Spinal and Epidural, in Pregnancy

Summary: the aim of the study is to observe the rate of postdural puncture headache observed after spinal anesthesia in cesarean section patients. two kind of spinal anesthesia needles will be used: 1. 26 gauge quincke (cutting-tip needle) 2. 26 gauge atraucan (atraumatic needle) the investigators will observe: 1. number of spinal punctures 2. time required for the spinal anesthesia procedure patients will be evaluated after 7 days for: 1. headache 2. backache

it is a known phenomenon that spinal anesthesia sometimes results in headache. the aim of the study is to observe the rate of postdural puncture headache observed after spinal anesthesia in cesarean section patients. two kind of spinal anesthesia needles will be used: 1. 26 gauge quincke (cutting-tip needle) 2. 26 gauge atraucan (atraumatic needle) we will observe: 1. number of spinal punctures 2. time required for the spinal anesthesia procedure patients will be evaluated after 7 days for: 1. headache 2. backache 2 kind of spinal anesthesia needles will be used, but no comparison will be made. this is an observational study. although literature gives different rates of postdural puncture headache for these two needles, we observe the same rate of headache in our clinical practice. we want to define the real rate of postdural puncture headache in patients undergoing cesarean section with spinal anesthesia.

Eligibility criteria:
inclusion criteria: * pregnant female patients between 18-40 years old undergoing cesarean section * patient accepting spinal anesthesia exclusion criteria: * infection at the spinal needle insertion cite * coagulability disorder * patient not accepting the procedure

Keywords: spinal anesthesia spinal needle cesarean section headache backache
electrocardiographic and electrophysiologic changes after percutaneous closure of atrial septal defect

Conditions: ASD; Brady Arrythmia

Summary: primary outcomes : determining the incidence of san and avn dysfunction before and after percutaneous asd closure comparing ecg and ep parameters of san and avn before and after percutaneous asd closure secondary outcomes : assessing clinical, echocardiographic and procedural risk factors affecting the avn function after asd closure device implantation determining the incidence of supraventricular arrhythmia inducibility before and after percutaneous asd closure

atrial septal defects (asds) are one of the most common types of acyanotic congenital heart diseases, comprising 6-10% all congenital heart defects. they represent the most common congenital heart disease diagnosed during adulthood. secundum asd is a defect in the fossa ovalis (septum primum), or the superior limb of the septum secundum and is the most common type of asd (80% of all asds). asd closure for secundum asd is recommended regardless of symptoms in patients with evidence of right ventricular (rv) volume overload and no pulmonary arterial hypertension (pah) or left ventricular (lv) disease. percutaneous device closure has become the first choice for secundum defect closure in presence of a feasible morphology with a reported low risk of serious complications (≤1% of patients). subclinical electrocardiography (ecg) abnormalities, sinoatrial node (san) and atrioventricular node (avn) conduction abnormalities have been reported in patients with asds. . the reported incidence of avn block following asd device closure varies widely from none up to 6.1%. high-grade avn block after device closure typically occurs in the first 24-hour post-procedure and may mandates device removal for resolution of heart block. the mechanism of avn block after asd device occlusion could be due to mechanical pressure on the av node or edema related to trauma. young age and large defect/device size may be a risk factor for avn block. deficient rims of the asd may also have an impact on development of avn block. whether or not there is a direct impact of asd device closure on the functional properties of avn and san is not well elucidated. testing the electrocardiographic and electrophysiologic (ep) parameters of avn and san before and after the procedure could obviously help understanding the real risk

Eligibility criteria:
inclusion criteria: * all patients presented with secundum asd eligible for percutaneous transcatheter asd closure at assiut university heart hospital exclusion criteria: * no exclusion

Keywords: asd epd brady arrythmia
a randomized placebo controlled trial on the efficacy of sustained natural apophyseal glide (snag) in low back pain patients

Conditions: Low Back Pain; Manual Therapy; Sustained Natural Apophyseal Glide (SNAG)

Summary: objectives: determine the efficacy of the snag technique (mulligan) applied to a subgroup of people with non-specific low back pain (lbp) on two new kinematic-algorythms, on pain, functional disability and kinesiophobia. design: a randomized double blinded placebo controlled trial with double arms in accordance with the consort statement. subjects: patients with non-specific low back pain will be recruting from saint-luc hospital, only a subgroup of them will be included according to specific inclusion criteria tailored for indication of application of snag's therapy (mulligan technique applied on the lumbar spine). method: subjects will be randomized in 2 groups; real-snag and sham-snag groups. all patients will be treated during a single session, and real/sham snag will be applied from a sitting position with the belt, and in a flexion direction. two kinematic-algorythms (rom and speed) from a validated kinematic spine model will be used and recorded with an opto-electronic device (bts-elite). pain at rest and during flexion, as well as functional disability and kinesiophobia will be recorded by self-reported measures. these outcomes will be blindly evaluated before and after treatment to compare both groups with " two-way-anova " statistic with for factors; time and groups.


Eligibility criteria:
inclusion criteria: * non-specific lbp, mechanical lbp with a pain in flexion direction, the pain in flexion is reduce with the application of snag therapy exclusion criteria: * specific lbp, non-mechanical lbp, the pain is not release in a flexion direction when snag is appllied

Keywords: low back pain manual therapy mulligan sustained natural apophyseal glide (snag) kinematic spine model
controlled ovarian stimulation and human uterine lavage

Conditions: Infertility, Female

Summary: this is a feasibility study intended to demonstrate the previvo uterine lavage system's ability to recover embryos from the uterus following either natural cycle (nc)/intrauterine insemination (iui), or controlled ovarian hyperstimulation (coh)/intrauterine insemination (iui).

the study is a prospective, multi- center, multiple-arm, feasibility study to evaluate the safety and efficacy of the previvo system in the recovery of embryos. this study will recruit up to 500 healthy premenopausal volunteers. subjects will undergo either natural cycle (nc)/intrauterine insemination (iui), or controlled ovarian hyperstimulation (coh)/intrauterine insemination (iui) and have the lavage procedure performed 4-6 days post iui. it is anticipated that embryos recovered will be cryopreserved for future use or donated for future use. subjects will be followed up with for up to 30 days after the lavage procedure. all data will be collected on paper crfs and analyzed by the principal investigator and study sponsor.

Eligibility criteria:
inclusion criteria: 1. premenopausal female 18-40 years of age 2. physically healthy and reasonably healthy family medical history 3. having both ovaries with patent fallopian tubes, no known reproductive problems 4. bmi between 18-35 kg/m2 5. presence of a normal uterine cavity as assessed by sonohysterogram (shg), hysterosalpingogram (hsg), or ultrasound 6. evidence of normal uterine anatomy that would not prevent the introduction of the lavage catheter. exclusion criteria: 1. history of, or presence of hydrosalpinx 2. addiction to alcohol and/or narcotics 3. had radiotherapy or chemotherapy 4. existence of an ovarian cyst at the beginning of cycle with suspicion of malignancy or a large benign cyst 5. contraindication for oral contraceptive pills or other study medication 6. clinically significant abnormal basic metabolic panel lab results 7. positive test or history of any of the following conditions: 1. human immunodeficiency virus (hiv) 2. hepatitis b infection 3. hepatitis c infection 4. syphilis (rpr) 5. chlamydial pelvic infection 6. gonorrheal pelvic infection. 7. positive pregnancy test 8. prior iud for 60 days or less, or one currently in place 9. allergic to study materials, supplies and medication 10. any active, uncontrolled, clinically significant medical condition as determined by the treating principal investigator

Keywords: uterine lavage intrauterine insemination embryo blastocyst in vivo superovulation
bp101 for adults with female sexual dysfunction

Conditions: Hypoactive Sexual Desire Disorder; Female Sexual Dysfunction; Sexual Desire Disorder

Summary: this study is to confirm efficacy and safety of study drug bp101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (hsdd). patients will be randomized in 1:1 ratio to either bp101 or placebo arms.


Eligibility criteria:
inclusion criteria: * women aged from 21 to 50 years old, who have signed informed concent, with a regular menstrual cycle (straw stages -5 to -3). * decrease or loss of sexual desire (icd-10 code: f-52.0) corresponding to the diagnosis of acquired generalized hypoactive sexual desire disorder (hsdd) according to diagnostic and statistical manual of mental disorders, 4th edition (dsm4), criteria. * current hsdd episode lasting not less than 24 weeks. * not less than 15 scores according to the fsds-r (distress) total score. * stable monogamous relationship with one sexually active male sexual partner lasting at least a year. the partner is physically available not less than 50% of time during a month. * consent to attempt to have a sexual intercourse at least twice a month, if she has a desire. * consent to complete a diary every day during the screening period and assessment of the baseline state (in this period diary records must cover ≥80% days), during the therapy and subsequent follow-up. * consent to use adequate methods of contraception throughout the study. exclusion criteria: * any prohibited treatments. * other mental disorders or psychiatric diseases. * diagnosed decrease or loss of sexual desire (hsdd) is situational (reactive) or lifelong. * score ≥ 20 according to the beck depression inventory during the screening. patients with 16 to 19 scores according to beck's inventory may be included in the study unless, in the investigator's opinion, an actual depressive disorder is observed in the patient. * inflammatory diseases of pelvic organs, infections of the genitourinary system, cervicitis, interstitial cystitis, vulvodynia or severe atrophy of the vaginal epithelium, precluding normal sexual activity. * surgical interventions (other than cosmetic surgeries) on reproductive organs in past medical history (ovariectomy, hysterectomy, obvious scars from childbirth-related perineal stitches, etc), resulting in pain/dyspareunia, and/or precluding sexual contacts, and/or requires hormonal replacement treatment, and/or lead to the loss of sensibility while sexual contact. * pregnant and nursing women or non-lactating women during the first 12 months after childbirth. * consumption of more than 5 portions of alcoholic drinks per week or alcohol addiction, drug addiction or drug abuse in the past. one portion of an alcoholic drink means 360 ml of beer, 120 ml of wine or 30 ml of a strong alcoholic drink.